• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Earnings And 2026 Guidance Might Change The Case For Investing In LeMaitre Vascular (LMAT)

    Simply Wall St·11/14/2026 00:48:25
    Listen to the news
    • LeMaitre Vascular reported third quarter 2026 results with sales of US$67.97 million and net income of US$15.02 million, and also affirmed a US$0.25 quarterly dividend payable in December 2026.
    • The company paired higher year to date sales and earnings with fresh 2026 guidance that leans on price driven organic growth and operating income expansion, which puts execution on margins and tissue supply projects under a brighter spotlight.
    • Investors will now evaluate how LeMaitre Vascular's updated 2026 earnings guidance could reshape the investment narrative built around pricing power.

    Scan how LeMaitre Vascular's pricing power story compares with other potential breakout opportunities across our curated list of 32 high quality undervalued stocks.

    LeMaitre Vascular Investment Narrative Recap

    To own LeMaitre Vascular, you need to be comfortable with a business that leans heavily on price driven organic growth and margin discipline. The analyst consensus Narrative on Simply Wall St frames the story around pricing power, tissue supply projects and international expansion. The latest quarter showed higher sales but lower quarterly net income versus last year, so the near term focus stays squarely on execution rather than headline growth.

    The updated 2026 guidance points to higher full year sales, operating income and EPS. This keeps the main short term catalyst tied to delivering those margin and earnings targets. The biggest near term risk remains operational hiccups, including tissue supply constraints and any regulatory or quality issues that could disrupt product availability or add cost. The new information does not change those core swing factors; it just sharpens the yardstick investors can use.

    The fresh full year 2026 outlook is the key announcement to watch. Management now expects US$247.7 million to US$276.8 million of sales, US$74.6 million to US$76.1 million of operating income and EPS of US$2.77 to US$2.82. Those numbers lean on pricing, product mix and the margin story that has been central to LeMaitre Vascular for several years.

    If you care about catalysts, that guidance effectively becomes a scorecard for the pricing power and relocalization themes described in the analyst consensus Narrative on Simply Wall St. Any slippage from tissue supply issues, regulatory costs or delays in broadening indications like Artegraft could make those ranges harder to reach. The Stifel conference appearance gives management another venue to explain how they see execution risk and timing on these projects.

    LeMaitre Vascular's current earnings are US$63.3 million, with analyst assumptions pointing to 9.6% yearly revenue growth and consensus earnings of US$85.3 million by 2029. This represents an increase of about US$22 million based on those projections and is tied to forecast revenues of US$354.2 million in the same year.

    Uncover why LeMaitre Vascular's fair value indicates a 28% potential upside to its current price before other investors react to that information.

    NasdaqGM:LMAT 1-Year Stock Price Chart
    NasdaqGM:LMAT 1-Year Stock Price Chart

    Exploring Other Perspectives

    For a very different angle, focus on Artegraft concentration risk. The most optimistic LeMaitre Vascular analysts were already baking in roughly US$354.4 million of revenue and US$88.5 million of earnings by 2029 before this guidance and the Stifel appearance. Those assumptions lean heavily on Artegraft success, and this week’s updates may later reshape them.

    Explore 4 other LeMaitre Vascular fair value estimates, including one that suggests as much as 69% upside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    • A great starting point for your LeMaitre Vascular research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • See our latest analysis for LeMaitre Vascular. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate LeMaitre Vascular's overall financial health at a glance.

    Looking for more LeMaitre Vascular style investment ideas?

    If LeMaitre Vascular has sharpened your focus on quality, use the Simply Wall St Screener to look for other stocks that match the kind of risk and reward balance you want in your portfolio.